Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Dimerix Limited ( (AU:DXB) ) has shared an update.
Dimerix Limited announced the quotation of 457,377 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to enhance its capital structure, potentially improving its market position and providing additional resources for its ongoing pharmaceutical development projects.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of pharmaceutical products. The company is primarily engaged in creating therapies for unmet medical needs, particularly in the areas of kidney disease and respiratory conditions.
Average Trading Volume: 3,224,904
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$332.2M
See more data about DXB stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue